Cellerant Therapeutics Appoints Key Research and Clinical Teams

Cellerant Therapeutics, Inc., a developer of therapies based on hematopoietic stem cells, has made two significant appointments to its research team, positioning the company for further advancements in cell products and cell-based therapies. Timothy C. Fong, PhD, has been named Vice President of Research, bringing expertise in hematology, oncology, and transplantation, while Linda F. Rogers, RN, joins as Senior Director of Global Clinical Operations, overseeing clinical trial management and operations.

Key Takeaways:

Timothy C. Fong, PhD, has been appointed Vice President of Research at Cellerant Therapeutics, bringing over 20 years of research experience in hematology, oncology, and transplantation from his previous positions at SangStat Medical Corporation, Aventis Gencell, and Chiron Corporation.
Linda F. Rogers, RN, has been appointed Senior Director of Global Clinical Operations, bringing expertise in clinical trial management and operations from her previous roles at SangStat Medical Corporation and Pharmacyclics.
Cellerant Therapeutics is focused on developing therapies based on hematopoietic stem cells (HSCs) for life-threatening diseases, including autoimmune disorders and cancer.
The company positions Fong and Rogers to contribute significantly to the development of cell products and cell-based therapies.
Cellerant's research team is led by Bruce Cohen, President and CEO, who welcomed Fong and Rogers, stating that they bring "significant research and clinical trial management expertise" to the company.

Statistics:

Over 20 years of combined research experience by Timothy C. Fong, PhD, and Linda F. Rogers, RN, in hematology, oncology, and transplantation.
Cellerant Therapeutics is focused on developing therapies for life-threatening diseases, including autoimmune disorders and cancer.
The company's research team is led by Bruce Cohen, President and CEO.

Sources:

NewsRx.com and NewsRx.net, June 28, 2004